Roche
NEWS
The Economist Intelligence Unit (EIU) has carried out two complementary studies on lung cancer in Latin America: an analysis of the economic costs and an assessment of the policy response (the Latin America Lung Cancer Traffic Lights).
Novo Nordisk is laying off 400 staffers so it can shift funds toward biological and technological innovation.
Days after a report by The New York Times and ProPublica revealed José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, failed to disclose his vast financial ties to various companies in journal articles, the noted cancer researcher has resigned from his position.
Last year’s influenza season in the U.S. had record-breaking hospitalization rates. A lot of industry observers are looking at a new flu drug, baloxavir marboxil, for which clinical trial data was just published.
Oncolytics Biotech® Inc. today announced that it has entered into a Master Clinical Supply Agreement (Agreement) with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq®) for use in the company’s clinical development program.
José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center came under fire this weekend for his failure to disclose financial ties to various pharmaceutical companies when he published research papers in peer-reviewed journals.
Let’s take a look at who made a splash in the pharma and biotech world the past week.
Six months after launching with $60 million, Cambridge, Mass.-based Rheos Medicines has tapped Roche veteran Sanjay Keswani as the startup’s new chief executive officer.
On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion.
JOBS
IN THE PRESS